1. Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study 
Arief Lalmohamed, PharmD, PhD, Imke Bartelink, PharmD, PhD, Liesbeth van Reij, PharmD, Christopher C. Dvorak, MD, Rada Savic, PhD, Juliëtte Zwaveling, PharmD, PhD, Robbert Bredius, MD, PhD, Antoine Egberts, PharmD, PhD, Marc Bierings, MD, PhD, Morris Kletzel, MD, FAAP, MBA, Peter Shaw, MD, Christa Nath, PhD, Georg Hempel, PhD, Marc Ansari, MD, Maja Krajinovic, MD, PhD, Tayfun Gungor, MD, Robert F. Wynn, MD, Paul Veys, MD, Geoff Cuvelier, MD, Robert Chiesa, MD, PhD, Mary Slatter, MD, Janel Long-Boyle, PharmD, PhD, Jaap Boelens, MD, PhD 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 2, Pages S102-S103 (February 2015)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Weibull model visualizing the relationship between busulfan exposure and the probability of EFS (highest EFS rates at mg*h/L, HR = 0.37, 95% CI compared to <50mg*h/L).
Biology of Blood and Marrow Transplantation  , S102-S103DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
Weibull models visualizing the relationship between busulfan exposure and EFS, by underlying disease.
Biology of Blood and Marrow Transplantation  , S102-S103DOI: ( /j.bbmt )
Copyright © Terms and Conditions